Ascendis Pharma A/S (NASDAQ:ASND) Posts Earnings Results

Ascendis Pharma A/S (NASDAQ:ASND) posted its quarterly earnings data on Thursday. The biotechnology company reported $1.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.89 by $1.05, FiscalAI reports. Ascendis Pharma A/S had a return on equity of 32.54% and a net margin of 70.99%. The business had revenue of $418.71 million for the quarter, compared to analysts’ expectations of $409.40 million.

Here are the key takeaways from Ascendis Pharma A/S’s conference call:

• Q3 product revenue rose 89% year over year to €366 million, including €291 million from YORVIPATH, €59 million from SKYTROFA and €16 million from newly launched YUVIWEL.
• YORVIPATH continued to grow, with U.S. demand described as steady and revenue increasing €39 million sequentially; the company said it expects further growth as it expands commercial availability, including 15 additional markets anticipated in 2027.
• YUVIWEL had about 340 U.S. patients enrolled through October, with more than 80% approved for reimbursement. Ascendis expects a European Commission decision before year-end and, if approved, plans a Germany launch in early 2027.
• Operating cash flow was €189 million in Q3, and Ascendis raised its 2026 expectation to at least €600 million; it ended the quarter with €964 million in cash. Management reiterated its longer-term revenue goals of more than €5 billion in 2030 and €10 billion in 2035, which depend on continued product growth, geographic expansion and pipeline development.
• The company is advancing label-expansion and combination-therapy programs, including a Phase III achondroplasia combination trial that has begun recruiting. Ascendis said the trial was redesigned after regulatory feedback to include a growth-hormone monotherapy arm, which enlarged the study and delayed it by a few months.

Ascendis Pharma A/S Trading Up 2.6%

Shares of NASDAQ:ASND traded up $6.80 during trading on Thursday, reaching $266.08. 718,268 shares of the stock were exchanged, compared to its average volume of 700,453. The firm’s 50-day moving average price is $242.59 and its 200 day moving average price is $239.48. The firm has a market cap of $16.60 billion, a price-to-earnings ratio of 20.67 and a beta of 0.40. Ascendis Pharma A/S has a 12-month low of $188.07 and a 12-month high of $282.15. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.32 and a current ratio of 2.99.

Analyst Upgrades and Downgrades

ASND has been the topic of several recent analyst reports. Canaccord Genuity Group set a $268.00 target price on Ascendis Pharma A/S in a research report on Monday, October 26th. BMO Capital Markets reissued an “outperform” rating on shares of Ascendis Pharma A/S in a research note on Thursday, September 10th. Citigroup lowered their price target on Ascendis Pharma A/S from $360.00 to $330.00 and set a “buy” rating for the company in a report on Monday, October 26th. Morgan Stanley dropped their price objective on shares of Ascendis Pharma A/S from $275.00 to $273.00 and set an “overweight” rating for the company in a research note on Tuesday, September 1st. Finally, TD Cowen reaffirmed a “buy” rating on shares of Ascendis Pharma A/S in a research note on Thursday, September 10th. Nineteen research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $305.95.

Insider Activity at Ascendis Pharma A/S

In related news, SVP Mads Bodenhoff sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $270.19, for a total value of $810,570.00. Following the transaction, the senior vice president owned 3,000 shares in the company, valued at approximately $810,570. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Jean-Jacques Bienaimé purchased 2,000 shares of Ascendis Pharma A/S stock in a transaction on Friday, August 14th. The shares were acquired at an average cost of $246.33 per share, for a total transaction of $492,660.00. Following the completion of the transaction, the director owned 2,900 shares of the company’s stock, valued at $714,357. This represents a 222.22% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Company insiders own 40.00% of the company’s stock.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a biopharmaceutical company headquartered in Denmark that develops medicines for rare diseases, with a focus on endocrinology. Founded in 2006, the company uses its TransCon technology platform to design therapies intended to provide sustained delivery of medicines. Its commercial products include SKYTROFA (lonapegsomatropin), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a treatment for adults with hypoparathyroidism.